Factors of occurrence and improvement methods of presenteeism attributed to diabetes: A systematic review

Koji Mori | Takahiro Mori | Tomohisa Nagata | Masako Nagata | Mahoko Iwasaki | Hiroki Sakai | Koki Kimura | Natsumi Shinzato

Department of Occupational Health Practice and Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan

Correspondence
Koji Mori, Department of Occupational Health Practice and Management, University of Occupational and Environmental Health, Kitakyushu, Japan. Email: kmori@med.uoeh-u.ac.jp

Funding Information
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for profit sectors.

Abstract
Objective: A systematic review was performed to study factors of occurrence and improvement methods of presenteeism attributed to diabetes.

Methods: We set 2 clinical questions; (a) how comorbidities and complications of diabetes induce presenteeism and (b) what interventions or conditions effectively improve presenteeism. Then, we conducted a comprehensive search with MEDLINE/ PubMed and Scopus databases and extracted those that met the clinical questions.

Results: Eighteen papers studied occurrence of presenteeism by comorbidities and complications of diabetes. Most studies were cross-sectional and had a low quality of evidence. However, the associations of hypoglycemia, diabetic neuropathy, and mood disorders with presenteeism were relatively well studied. The papers that discussed effective interventions or conditions for improving presenteeism were very limited.

Conclusions: Our review suggests that presenteeism attributed to diabetes is mainly caused by hypoglycemia, diabetic neuropathy, and mood disorders. There are very limited evidences, but available information suggests that improving glycemic control, adjusting treatment regimen by evaluating the impact on work, providing psychological support, and developing suitable work accommodations may effectively reduce presenteeism.

KEYWORDS
comorbidity, complication, diabetes mellitus, presenteeism, work productivity

1 INTRODUCTION

Diabetes is one of the most common chronic diseases in nearly all countries and has been increasing globally.1,2 The increase in diabetes is a considerable economic burden for patients/employees, employers, and society. The American Diabetes Association (ADA) has estimated economic costs of diabetes in the United States (US) every 5 years since 1997.3-7 The costs of diabetes have also been estimated in several European countries (Norway,8 Sweden,9 The Netherlands,10 Spain,11 and Poland12) and others (Argentina13 and Mali14). The costs usually consist of direct medical costs and indirect costs attributed to diabetes. Although direct costs are substantial, indirect costs occupy a significant part of total costs in the entire population. Goetzel et al have continued to estimate the costs of common chronic conditions from employers’ aspects in the US since 1996.15-17 Considering that it was effective for employers to understand total work productivity costs for
better decision making, they added presenteeism attributed to chronic diseases, such as diabetes, hypertension, depression, and arthritis, to the estimation. In the study, like other diseases, presenteeism accounts for a large proportion of total costs of diabetes, reaching 62% of total costs and 87% of indirect costs among a database of employees in large US corporations. The trend was reflected in ADA’s estimation, and the organization added presenteeism as an indicator of reduced performance at work to indirect costs in its 2007, 2012 and 2017 estimations, which comprised 34%, 30%, and 30% of indirect costs, respectively.

Work productivity loss often consists of absenteeism and presenteeism. While absenteeism is to be absent from work due to health problems, presenteeism is defined as the health-related productivity loss at paid work. Presenteeism can also be said as difficulty in doing work due to illness or symptoms, and is measured with various self-reported instruments. In many industrialized countries including Japan, the working population is aging, and it is expected that more workers will continue to work while undergoing treatment for diseases. Diabetes is one such disease. When considering the significant burden of presenteeism attributed to diabetes, counteractive measures are necessary in the workplace as well as for disease prevention. In order to provide support for such workers to demonstrate their performance in the workplace, it is considered effective to clarify factors that create difficulty in doing work due to disease itself or its treatment. Breton et al conducted a systematic review on burden of diabetes on the ability to work in 2011 and identified only one research on the occurrence of presenteeism by comorbidities of diabetes that is a cross-sectional study observing that individuals with diabetes and neuropathic symptoms were found to have more work performance loss than those without diabetes. However, we expected that most of targeted studies had been published after the review.

Therefore, we conducted a systematic review on the occurrence of presenteeism by comorbidities and complications of diabetes and interventions for improving presenteeism.

2 | MATERIALS AND METHODS

This systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA). We set the following two clinical questions to achieve our research objectives: (a) how comorbidities and complications of diabetes induce presenteeism and (b) what interventions or conditions effectively improve presenteeism attributed to diabetes.

On August 15, 2018, we searched MEDLINE/PubMed and Scopus databases for studies published from their start date to August 15, 2018. In some studies, absenteeism and presenteeism were not separated, and are expressed as work productivity loss. The loss from presenteeism attributed to chronic conditions were usually much bigger than absenteeism. Therefore, studies were included if they described an observational and intervention study where presenteeism or health-related productivity loss including presenteeism was evaluated among workers with diabetes. In addition, as some tools measuring work productivity loss use terms such as work impairment as synonyms with presenteeism, we decided to take them together. The database search was performed with the following search term and limited to “Human” (“diabetes”[MeSH Terms] OR “diabetes “[All Fields] OR “hypoglycemia”[MeSH Terms] OR “hypoglycemia”[All Fields] OR “hyperglycemia”[MeSH Terms] OR “hyperglycemia”[All Fields]) AND (“presenteeism”[MeSH Terms] OR “presenteeism”[All Fields] OR “productivity”[MeSH Terms] OR “productivity”[All Fields] OR “work ability”[All Fields] OR “work impairment”[All Fields] OR “work performance”[All Fields] OR “work limitation”[All Fields] OR “work loss”[All Fields]).

First, two researchers (TM and TN) independently collected studies from those identified by the above literature search that evaluated the association between diabetes and productivity loss by the titles. When the opinions of the two researchers differed, the paper was included. Second, two researchers (KM and TM) independently selected studies that met inclusion and exclusion criteria from the abstracts. The inclusion criterion was any study that evaluated the association between diabetes and labor productivity or work ability in peer-review journals. Exclusion criteria included papers examining medical costs (direct costs) only and papers written in languages other than English. Papers were also excluded when we could not judge the inclusion/exclusion criteria from the abstract only. When the opinions of the two researchers differed, the paper was also included. After including possible papers identified from references of the related papers in our search, one of researchers read the full text of the screened studies and we discussed when the assigned researcher judged it did not meet criteria at researchers’ conference. Finally, we selected papers that studied the occurrence of productivity loss including presenteeism by comorbidities and complications of diabetes and those that discussed effective interventions or conditions for improving presenteeism attributed to diabetes. Study selection was performed as shown in Figure 1.

We assessed the quality of selected papers on the occurrence of productivity loss including presenteeism by comorbidities and complications of diabetes using the Newcastle Ottawa Scale (NOS) for cohort studies. However, as the NOS was originally developed for cohort studies and case-control studies, we used the modified NOS by Breton et al for cross-sectional studies. These scales address three domains: (a) selection of study groups (four items for cohort studies)
studies and three items for cross-sectional studies), (b) comparability of these groups (one item for both studies), and (c) ascertainment of either exposure or outcome of interest (three items for cohort studies and one item for cross-sectional studies). A study could be awarded a maximum of 1 star for each item within the selection and outcome categories and a maximum of 2 stars for comparability. The overall quality rating was calculated as the sum of stars (maximum of 9 stars for cohort studies and 6 stars for cross-sectional studies). Interventions and conditions differed among papers on effective interventions or conditions for improving presenteeism attributed to diabetes. Thus, we judged quality of evidence was judged with NOS for a cohort study and a cross-sectional study and the risk of bias was judged with the Cochrane Handbook for Systematic Reviews, Version 5.1.0 for interventions.29

3 | RESULTS

We found 18 papers that studied the occurrence of productivity loss including presenteeism by comorbidities and complications of diabetes (Table 1). Sixteen papers were cross-sectional studies and 7 of them did not mention the control group. Two were cohort studies. Most of the papers had relatively low qualities of evidence which were evaluated by NOS as shown in Table 1. We also identified 5 papers that discussed effective interventions or conditions for improving presenteeism
attributed to diabetes (Table 2). Of them, there were a cross-
sectional study and a cohort study, and their qualities of
evidence evaluated by NOS were shown in Table 2. Three 
were interventions, and they were a randomized control trial, a 
non-randomized control trial, and a pre-post intervention 
comparison study. Their risks of bias were high.

Also, among the 23 papers, 12 papers were focused on
type 2. However, type 1 and type 2 were combined in 5 pa-
ners and the type with diabetes was not clarified in 5 papers. 
Therefore, we decided not to be conscious of the type of di-
babetes mellitus.

3.1 Occurrence of productivity loss

DiBonaventura et al30 studied loss of work productivity of
type 2 diabetes associated with tolerability issues of oral anti-
diabetic agents. As the number of tolerability issues increased, 
presenteeism worsened after adjusting for demographics, co-
morbidities of diabetes, and disease characteristics. Patients 
with 1, 2, 3, and 4 or more issues were projected to have pres-
enteeism costs that were $1583, $3662, $5940, and $6190 
or greater, respectively, and these costs were much higher 
than absenteeism costs. Although not specific for presentee-
ism, hypoglycemia, headache, water retention (edema), and 
weight gain were the only tolerability issues significantly as-
associated with greater total work impairment.

Comorbidities and complications whose effects on pre-
 senteeism were relatively well studied included hypoglyce-
mia, neuropathy, and mental disorders, mainly depression. 
Nine papers evaluated effects of hypoglycemia on work pro-
ductivity including presenteeism. Brod et al31 reported that 
among individuals reporting a non-severe hypoglycemia 
event (NSHE) at work, 23.8% reported missing a meeting 
or work appointment or not finishing a work task on time. 
Among respondents experiencing an NSHE outside working 
hours (including nocturnal NSHE), 31.8% reported that 
they missed a meeting or work appointment or did not fin-
ish a work task on time due to the nocturnal NSHE. Brod et 
al32,34 also reported that the impact of non-severe nocturnal 
hypoglycemia events (NSNHE) was apparent for those who 
worked the next day in the US, Canada, and European Union 
countries. When compared with respondents with type 1 di-
betes, those with type 2 appeared to experience more pre-
senteeism associated with an NSNHE. Brod et al32,34 also re-
ported that the impact of non-severe nocturnal hypoglycemia 
events (NSNHE) was apparent for those who worked the next day in the US, Canada, and European Union countries. 
When compared with respondents with type 1 diabetes, 
those with type 2 appeared to experience more presenteeism 
associated with an NSNHE. Also, US respondents were 
least likely to report presenteeism, and respondents from 
France had the highest rate of presenteeism when comparing 
4 countries, ie, USA, UK, Germany, and France.32 The 
impact of the NSNHE on presenteeism was higher than that for 
groups defined as normal controls in two recent studies when 
evaluated with Endicott Work Productivity Scale scores.33,34 
Moreover, 25.0% of the subjects reported that the NSNHE 
had a high impact on productivity at work the following day, 
32.1% reported a moderate impact, 18.9% reported a little 
impact, and 24.0% reported no impact with Likert scale as-
essment.33 However, Ohaski et al35 evaluated the impact last 
NSHE on presenteeism by a question on missing a meeting/ 
work appointment or failing to finish a task in Japanese pop-
ulation, and observed 25% of respondents with last daytime 
were missing a meeting/work appointment or failing to finish 
a task, but only 2% with last night-time NSHE were reported 
the impact. Meneghini et al36 categorized type 2 diabetes pa-
tients in the US based upon self-reported experience in the 
past 3 months, and reported that patients with severe hypogly-
cemia had significantly greater presenteeism compared with 
patients with non-severe or no hypoglycemia, but there was 
no significant difference in presenteeism between non-severe 
and no hypoglycemia. Pawaskar et al37 also reported similar 
results from US population. Mitchell et al38 analyzed self-
reported hypoglycemic episode at 6 follow-up assessments 
separated by 4 weeks in the United Kingdom. At the baseline 
survey, about 35.3% of employed respondents who experi-
cenced at least 1 hypoglycemia experience (HE) in the month 
had work impairment in the prior 7 days, which was approx-
imately double of those without HE. However, there was no 
significant difference in work impairment between those with 
HE and without HE during the follow-up period, although 
the analysis included only a small number of samples who 
completing all surveys. Lopez et al39 compared presenteeism 
attributed to diabetes among those who had experienced hy-
poglycemia in the previous 3 months (recent), in the past but 
not in the previous 3 months (non-recent), and those who had 
ever experienced hypoglycemia (never). The recent group 
did significantly higher presenteeism (21.3%) compared with 
those in non-recent (15.1%) or never (14.0%) groups.

Five papers assessed the effects of diabetic neuropathy 
on work productivity including presenteeism attributed to 
diabetes. Stewart et al22 reported that those with neuropathic 
symptoms were substantially more likely to report the need 
to change the number of hours worked or their jobs and that 
there was a moderate-to-severe impact on their job per-
fomance in 1 US population-based study. DiBonaventura 
et al40 compared presenteeism among the healthy con-
trol group, diabetes without painful peripheral neuropathy 
(pDPN) group, and pDPN group across 3 years and reported 
that both the control and diabetes without pDPN groups 
reported significantly lower levels of presenteeism than the 
pDPN group. The other papers were clinic-based studies. 
Gore et al41 observed 64.4% patients with pDPN among 
those who worked reported work productivity loss due to 
the symptom and accomplished less at work an average of 
15.2 days in the preceding 3 months. Taylor-Stokes et al42 
analyzed self-reported data from employed individuals 
diagnosed as pDPN and reported impairment while work-
ing increased as pDPN severity levels worsened. Estimated 
loss productivity and annual related costs were 21.0% and 
$8266, 33.7% and $15 449, and 60.5% and $24 300 for mild,
| Comorbidities or complications | Authors | Year published | Country of study | DM type | Data source/sample recruitment |
|--------------------------------|---------|---------------|------------------|---------|-------------------------------|
| Tolerability issues with oral antidiabetic agents (e.g., constipation or diarrhea, headache, loss of appetite, nausea or vomiting, upper respiratory tract infection, genitourinary tract infections, water retention or edema, unintended weight loss/gain, yeast infections, hypoglycemia, and cardiovascular events) | DiBonaventura et al 30 | 2011 | USA | Type 2 | Invited T2DM patients identified from 3 other surveys via e-mail |
| Hypoglycemia | | | | | |
| Self-reported non-severe hypoglycemia event (NSNHE): a hypoglycemic situation in which the patient had low blood glucose but did not require help from anyone else to manage the episode | Brod et al 31 | 2011 | USA, UK, Germany, France | Types 1 and 2 | Recruited subjects online via a wide range of permission, e-mail recruitment, affiliate networks, and website advertising |
| Self-reported NSNHE: a night-time hypoglycemic episode that occurred while sleeping and did not require medical attention or did not require help from anyone else to manage the hypoglycemia | Brod et al 32 | 2012 | USA, UK, Germany, France | Types 1 and 2 | Recruited respondents from a variety of online venues, including website advertising, affiliate networks and email recruitment, and via face-to-face or telephone interview |
| Self-reported non-severe nocturnal hypoglycemia event (NSNHE): a night-time hypoglycemic episode that occurred while sleeping and did not require medical attention or did not require help from anyone else to manage the episode | Brod et al 33 | 2013 | USA, Canada, UK, Germany, France, Italy, Spain, The Netherlands, Sweden | Types 1 and 2 | Recruited subjects from more than 100 websites as well as from face-to-face and telephone surveys. |
| Sample size | Measure of presenteeism | Key conclusions on presenteeism | Research design | Quality of evidence |
|-------------|-------------------------|---------------------------------|------------------|--------------------|
| 2074 eligible patients among 4316 respondents from 10374 contacted | Work productivity and activity impairment questionnaire (WPAI) | As the number of tolerability issues increased, presenteeism worsened by 8.65%, 14.99%, 20.08%, and 21.96% for those with 1, 2, 3, and 4 or more issues, respectively, after adjusting for demographics, comorbidities, and disease characteristics. When monetizing, total annual adjusted presenteeism costs were $1585, $3662, $5940, and $6190 or greater for patients, respectively. | Cross-sectional study | 4/6 |
| A total of 6756 respondents with self-reported diabetes were screened. Of these, 2669 reported an NSNHE during the last month, 1431 reported working for pay; 1404 respondents were finally analyzed after excluding those who did not remember | Evaluated impact on work productivity by reports of missing a meeting or work appointment or not finishing a work task on time | Lost productivity was estimated to range from $15.26 to $93.47 per NSHE, representing 8.3-15.9 h of lost work time per mo. Among individuals reporting an NSNHE at work (n = 972), 23.8% (n = 231) reported missing a meeting or work appointment or not finishing a work task on time. Among respondents experiencing an NSNHE outside working hours (including nocturnal; n = 612), 31.8% (n = 197) reported that they missed a meeting or work appointment or did not finish a work task on time due to the nocturnal NSHE. | Cross-sectional study | 1/6 |
| A total of 6756 respondents with diabetes were screened. Of these 2600 (1280 type 1 and 1320 type 2) had experienced one or more NSHE at any time in the past month. Of these respondents, 1086 (676 type 1 and 410 type 2) indicated that they had experience one of more NSNHE while asleep at night | Evaluated the impact by a question on missing a meeting/work appointment or failing to finish a task | Compared with respondents with type 1 diabetes, those with type 2 appeared to experience more presenteeism associated with an NSNHE (8.7% vs 14.4%). US respondents were least likely to report presenteeism, and respondents from France had the highest rate of presenteeism. | Cross-sectional study | 1/6 |
| A total of 20 212 respondents with self-reported diabetes were screened. Of these 2673 respondents who reported an NSNHE during the last month, 2108 patients completed the survey; 1100 reported working for pay | Endicott Workplace Productivity Scale (EWPS) and Likert scale assessment with the question “How much has this NSNHE impacted productivity at work?” | For those who worked the next day, the impact of the previous night event was apparent, with 42.6% reporting that they had trouble focusing or concentrating at work the next day, 20.1% reporting they could not complete work tasks on time, and 15.6% reporting they needed to reschedule their work time. Additionally, 25% of the respondents reported that the NSNHE had a high impact on work productivity the following day, 32.1% reported a moderate impact, 18.9% reported a low impact, and 24.0% reported no impact. Based on EWPS scores, the impact on presenteeism had a mean score of 21.3 (SD = 21.0), which was significantly higher than those for groups defined as normal controls (ranging from mean 3.54 and mean 15.6 (SD = 11.7) to 18.2 (SD = 10.7)) | Cross-sectional study | 1/6 |

(Continues)
| Comorbidities or complications | Authors | Year published | Country of study | DM type | Data source/sample recruitment |
|-------------------------------|---------|----------------|------------------|---------|-------------------------------|
| Self-reported NSNHE: a nighttime hypoglycemic episode that occurred while sleeping and did not require medical attention or did not require help from anyone else to manage the hypoglycemia | Brod et al | 2013 | Canada | Types 1 and 2 | Recruited subjects from more than 100 websites as well as from face-to-face and telephone surveys |
| Self-reported hypoglycemia episode | Mitchell et al | 2013 | UK | Type 2 | Identified potential respondents through the 2011 5EU National Health and Wellness Survey (NHWS) and the diabetes chronic ailment panel of Light Speed Research in the UK. Invitation emails were sent to 7144 panelists who indicated that they had diabetes |
| Self-reported hypoglycemia episode | Lopez et al | 2014 | USA | Type 2 | Used data from the 2012 US NHWS. In the survey, participants were recruited through opt-in emails, co-registration with other panels, e-newsletter campaigns, and online banner placements |
| Self-reported NSHE | Ohashi et al | 2017 | Japan | Types 1 and 2 | Recruited respondents through multiple online channels, such as website advertising, permission emailing, and affiliate networks |
| Self-reported hypoglycemia event | Meneghini et al | 2017 | USA | Type 2 | Used data from the 2011, 2012, and 2013 US NHWS. Potential respondents were identified through the general panel of Lightspeed Research |
| Sample size | Measure of presenteeism | Key conclusions on presenteeism | Research design | Quality of evidencea |
|-------------|-------------------------|--------------------------------|----------------|---------------------|
| A total of 2279 respondents with self-reported diabetes were screened, of which 239 reported an NSNHE during the previous month. Of the 239 respondents, 200 completed the survey and 87 reported working for pay | EWPS and Likert scale assessment with the question “How much has this NSNHE impacted work productivity?” | For those who worked the next day, the impact of the previous night’s event was apparent, with 44.8% reporting they had trouble focusing or concentrating the next day at work, 24.1% reporting they could not complete work tasks on time, and 18.4% reporting they needed to reschedule their work day. Additionally, 33.3% reported that NSNHEs had a high impact on work productivity the following day, 33.3% reported a moderate impact, 17.2% reported a low impact, and 16.1% reported no impact. Based on EWPS scores, the impact on presenteeism had a mean score of 24.1 (SD = 21.6), which was significantly higher than those for groups defined as normal controls in two recent studies [ranging from mean 3.54 and 15.6 (SD = 11.7) to 18.2 (SD = 10.7)] | Cross-sectional study | 1/6 |
| Those who gave consent were screened for a physician diagnosis and current use of prescription medications. Respondents who used only oral medicine were excluded. The remaining participants were directed to the baseline questionnaire. Among 1329 respondents who completed the baseline survey, 448 were employed. Five follow-up assessments separated by 4 weeks were completed by 836, 759, 765, 511, and 451 respondents | WPAI | At the baseline survey, about 35.5% of employed respondents experienced ≥1 hypoglycemia experience (HE) in the month prior to the survey, which was approximately double the work impairment in the prior 7 d experienced by those without ≥1 HE (16.6%). However, there was no significant difference in work impairment between those with ≥1 HE (n = 83) and without HE (n = 72) during the study among those completing all study surveys. Baseline comparisons showed that worse HbA1c and greater healthcare resource use was associated with HE | Cohort study | 3/9 |
| Among 71 157 participants, a total of 7239 participants reported a diagnosis of type 2 DM, and 6065 were treated with antihyperglycemic agents. Additionally, 5756 knew their hypoglycemia status; 1688 had experienced hypoglycemia within the previous 3 mo (recent), whereas 1516 had experienced hypoglycemia in the past but not in the previous 3 mo (non-recent) and 2552 had never experienced hypoglycemia (never) | Presenteeism was defined as the percentage of overall work impaired by hypoglycemia-related health issues | Those with recent hypoglycemia had significantly higher presenteeism (21.3%) compared with those with non-recent hypoglycemia (15.1%) or never (14.0%). Compared with those who never experienced hypoglycemia, those who experienced hypoglycemia tended to be more aware of their HbA1c levels, have higher HbA1c levels, and were less adherent to their antihyperglycemic medications | Cross-sectional study | 2/6 |
| A total of 411 respondents among 3145 screened met inclusion criteria that were treatment with insulin aged 20 y old and above and completed the survey | Evaluated the impact by a question on missing a meeting/work appointment or failing to finish a task | As for last daytime NSHE, 25% of respondents were missing a meeting/work appointment or failing to finish a task. As for last night-time NSHE, only 2% were reported the impact | Cross-sectional study | 2/6 |
| A total of 17 676 unique respondents were identified, and of whom 2423 met inclusion criteria. Patients were categorized into “no hypoglycemia in the past 3 mo (n = 938), non-severe hypoglycemia (n = 1335), and severe hypoglycemia (n = 150) | Work Productivity and Activity Impairment questionnaire (WPAI) | Patients with severe hypoglycemia (adjusted mean 33.7%) had significantly greater presenteeism compared with patients with non-severe (18.6%) or no hypoglycemia (15.5%), but there was no significant different in presenteeism between non-severe and no hypoglycemia | Cross-sectional | 4/6 |

(Continues)
| Comorbidities or complications                                                                 | Authors                        | Year published year | Country of study | DM type     | Data source/sample recruitment                                                                                   |
|------------------------------------------------------------------------------------------------|-------------------------------|---------------------|------------------|-------------|----------------------------------------------------------------------------------------------------------------|
| Self-reported hypoglycemia event (Severe hypoglycemia was based on the need for external assistance) | Pawaskar et al 37             | 2018                | USA              | Type 2      | Used data from the 2013 US NHWS. Patients with Type 2 diabetes were identified by their answers               |
| Painful diabetic distal symmetrical sensorimotor polyneuropathy (DPN) (Community-based practitioners diagnosed) | Gore et al 41                 | 2006                | USA              | Not Specific | Recruited by 17 community-based practitioners from settings across the US                                     |
| Self-reported diabetes-related neuropathy (respondents reported in the affirmative to the question on sensory symptoms) | Stewart et al 22              | 2007                | USA              | Not specific | Used data of American Productive Audit, which was a national random-digit-dial telephone survey of US population. A total of 42 107 interviews were completed. Of these, 36 634 were eligible based on occupation |
| Painful diabetic peripheral neuropathy (self-administered questionnaire)                           | DiBonaventura et al 40        | 2011                | USA              | Type 2      | Obtained data through an annual cross-sectional study across the US. The sample was identified through a web-based consumer panel. Participants who completed 3 consecutive waves were included |
| Painful diabetic peripheral neuropathy (pDPN) (with a confirmed diagnosis by physicians)          | Taylor-Stokes et al 42        | 2011                | France, Germany, Italy, UK | Not specific | Collected data in clinical practice settings by physicians. Patients were invited to participate by completing questionnaires |
### Table 1: Sample size, Measure of presenteeism, Key conclusions on presenteeism, Research design, and Quality of evidence

| Sample size                                                                 | Measure of presenteeism | Key conclusions on presenteeism                                                                                                                                                                                                 | Research design | Quality of evidence |
|-----------------------------------------------------------------------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|---------------------|
| The analysis included 3630 participants—1729 of whom reported having non-severe hypoglycemia and 172 of whom had severe hypoglycemia in the previous 3 mo. Among survey participants, 1130 (31.3%) were employed | Work Productivity and Activity Impairment questionnaire (WPAI) | Presenteeism were significantly associated with severity of hypoglycemia event (no hypoglycemia 17.7%, non-severe hypoglycemia 18.7%, and severe hypoglycemia 31.2%). Mean annualized costs due to presenteeism also increased with increasing severity of hypoglycemia (no hypoglycemia $5600.70, non-severe hypoglycemia $6263.30, and severe hypoglycemia $9090.00) | Cross-sectional | 4/6                 |
| Among 265 patients who met all study eligibility criteria, 255 returned completed surveys. In the preceding 3 mo, 73 of patients worked either part-time or full-time | Evaluated by the question, days accomplished less at work | Among patients who worked, 64.4% reported work productivity loss due to painful DPN and accomplished less at work an average of 15.2 (SD = 18.5) d in the preceding 3 mo | Cross-sectional    | 2/6                 |
| The study included 19 075 occupation-eligible individuals 40-65 y of age. All analyses compared those without self-reported diabetes (n = 18 042), individuals with diabetes but without neuropathic symptoms (n = 642), and individuals who reported both diabetes and neuropathic symptoms (n = 391) | Hour-equivalent per week of health-related reduced performance on days at work was determined. Presenteeism was quantified by the occurrence of 5 specific work behaviors (losing concentration, repeating a job, working more slowly than usual, feeling fatigued at work, and doing nothing at work) and the average amount of time between arriving at work and starting to work on days not feeling well | Among the respondents with diabetes who remained in the workforce, those with neuropathic symptoms were substantially more likely to report the need to change the number of hours worked (11.5% vs 4.4%) or their jobs (10.7% vs 4.4%) and that there was a moderate-to-severe impact on their job performance (11.6% vs 3.9%) compared with those without neuropathic symptoms | Cross-sectional study | 5/6                 |
| Participants were categorized into 1 of 3 groups: those with pDPN (n = 290), those with type 2 diabetes but without pDPN (n = 1037), and those not diagnosed with type 2 diabetes (control group; n = 8162). Among them, only employed patients were measured for work productivity loss | WPAI | Across the 3 y, both the control and diabetes without pDPN groups reported significantly lower levels of presenteeism (12.8% and 13.5%, respectively) than the pDPN group (17.8%) | Cohort study       | 5/9                 |
| In this study, 634 individuals identified as having a confirmed diagnosis of pDPN, 124 of whom were employed individuals and had available WPAI data | WPAI | Employed individuals reported greater impairment while working at increasing pDPN severity levels. Estimated loss productivity and annual related costs among employed individuals were 21.0% and $8266, 33.7% and $15449, and 60.5% and $24300 for mild, moderate, and severe pDPN, respectively. These costs appeared to be primarily driven by presenteeism | Cross-sectional study | 3/6                 |

(Continues)
TABLE 1  (Continued)

| Comorbidities or complications | Authors | Year published | Country of study | DM type | Data source/sample recruitment |
|--------------------------------|---------|----------------|------------------|---------|-------------------------------|
| Peripheral diabetic neuropathy (diagnosed with pDPN at least 6 mo earlier) | Sadosky et al 43 | 2013 | USA | Not specific | Recruited subjects during routine visits from general practitioner and specialists sites |
| | Bielecky et al 44 | 2016 | Canada | Not specific | Used cross-sectional secondary data from the 2003, 2005, 2007, 2009, and 2010 cycles of the Canadian Community Health Survey in which data were collected through interview |
| Poor and very poor mental well-being (evaluated using the mental component summary) | Bolge et al 45 | 2016 | USA | Type 2 | Used data from the 2013 US NHWS, an annual, cross-sectional study of the US adult population Data were collected through a self-administered internet-based questionnaire |

Mental conditions

| Mental conditions | Authors | Year published | Country of study | DM type | Data source/sample recruitment |
|-------------------|---------|----------------|------------------|---------|-------------------------------|
| Mood disorders including depression, bipolar disorder, mania, or dysthymia (self-reported through interview) | Bielecky et al 44 | 2016 | Canada | Not specific | Used cross-sectional secondary data from the 2003, 2005, 2007, 2009, and 2010 cycles of the Canadian Community Health Survey in which data were collected through interview |
| Poor and very poor mental well-being (evaluated using the mental component summary) | Bolge et al 45 | 2016 | USA | Type 2 | Used data from the 2013 US NHWS, an annual, cross-sectional study of the US adult population Data were collected through a self-administered internet-based questionnaire |
| Cognitive impairment | Lee et al 46 | 2017 | Canada | Type 2 | Selected individuals as a part of a motivation study through employers’ third-party health insurance providers and/or directly by the project team |

Quality of evidence was evaluated with the Newcastle Ottawa Scale and is expressed as number of stars gained/maximum number of stars for each study type.

Moderate, and severe pDPN, respectively. The authors also mentioned that costs appeared to be primarily driven by presenteeism. Sadosky et al 43 also observed mean overall work impairment as pain severity increased but did not note a significant difference, likely due to the small number of subjects employed for pay.

Two papers studied effects of mental conditions on presenteeism attributed to diabetes. Bielecky et al 44 reported that respondents with both diabetes and mood disorder including depression, bipolar disorder, mania, or dysthymia have higher presenteeism and fully adjusted prevalence ratio than those with either diabetes or mood disorder only. However, a significant negative interaction was observed with the combination of the two conditions. Bolge et al 45 reported that those with very poor mental well-being evaluated by the mental component summary had higher presenteeism than those with poor and good mental well-being, and those with poor mental well-being had higher presenteeism than those with good mental well-being.

Lee et al 46 evaluated the mediational effect of depressive symptoms and cognitive impairment on work productivity to understand the mechanistic link between diabetes and work productivity loss. Self-rated depressive and cognitive symptoms were positively correlated with work impairment among subjects with or at risk for diabetes and cognitive impairment severity partially but significantly mediated the association between depressive symptom severity and work impairment.

3.2 Effective interventions or conditions

There are two main approaches that improve productivity loss including presenteeism, i.e., approaches to individuals and those to work accommodations. Among 5 papers, 4 were
| Sample size | Measure of presenteeism | Key conclusions on presenteeism | Research design | Quality of evidence |
|-------------|-------------------------|--------------------------------|----------------|--------------------|
| Among 112 subjects, 20 were employed for pay | WPAI-Specific Health Problem | Mean overall work impairment among subjects employed for pay was 43.6%, which worsened as pain severity increased. However, this difference was not significant due to the small number of subjects | Cross-sectional study | 3/6 |
| Among 132 072 eligible respondents, 120 005 respondents who met inclusion criteria were used in the analysis | Evaluated by the question, “Does a long-term physical condition, mental condition, or health problem reduce the amount or kind of activity you can do at work?” “Sometimes” or “often” were classified into presenteeism, and “never” was classified into no presenteeism | About 37.6% of respondents with both diabetes and a mood disorder have presenteeism. The fully adjusted prevalence ratio of the group was 1.78, which was significantly higher than those with either diabetes or diabetes. However, a significant negative interaction was observed between the 2 conditions | Repeated cross-sectional study | 5/6 |
| Among 7852 respondents, 1701 experienced very poor mental well-being, 1781 poor mental well-being, and 4370 good mental well-being | WPAI-General Health questionnaire | Respondents with very poor mental well-being had higher presenteeism than those with poor and good mental well-being. Additionally, respondents with poor mental well-being had higher presenteeism than those with good mental well-being | Cross-sectional study | 4/6 |
| A total of 3627 individuals were screened, 1738 met eligibility criteria, and 724 consented. Among them, 205 subjects with pre/diabetes were included in the study | EWPS | Self-rated depressive and cognitive symptoms were positively correlated with work impairment among subjects with or at risk for diabetes. Self-rated measures of cognitive impairment mediated the association between depressive symptom severity and workplace impairment | Cross-sectional study | 3/6 |

related to individual approaches and the other was related to work accommodations.

Loeppke et al. analyzed medical pharmacy claims data from large corporations including health risk appraisal and reported medication adherence is a significant predictor of job performance for the type 2 diabetes with insulin, oral hypoglycemic agent, or metformin group. Katcher et al. studied the effects of a vegan nutrition program for individuals with body mass index $\geq 25 \text{ kg/m}^2$ and/or previous diagnosis of type 2 diabetes at a large corporate site on work productivity, and participants in the vegan diet group reported a 40% decrease in the number of health problems affecting work productivity. Adepoju et al. compared presenteeism among subjects aged $\geq 18$ years with type 2 diabetes randomized into 4 study arms: 1 usual care arm and 3 self-management program arms. There were no statistically significant differences among the groups, although presenteeism was calculated with a multiplication factor obtained from prior literature. Bevis et al. provided 12 months wellness programs including screening and measurement of baseline indices, educational sessions, telephonic support, quarterly laboratory monitoring, and provision of glucometers and test stripes to employees with diabetes at a major employer in the US. There was significant improvement in both HbA1c levels and presenteeism scoring between pre- and postintervention. They reported that improved stress management and perceived improvement in health were the major contributors to improved presenteeism scoring.

As for work accommodations, Gifford et al. observed 5.11 times greater odds that an employee who did not receive a needed accommodation experienced a higher level of lost productivity than an employee who received a needed accommodation. However, they found no interactions between chronic health problems including metabolic condition and accommodations.
| Conditions or interventions | Authors                | Year published | Country of study | DM type and other conditions | Data source/sample recruitment |
|-----------------------------|------------------------|----------------|------------------|------------------------------|--------------------------------|
| Medical adherence           | Loepke et al 47        | 2011           | USA              | Type 2                       | Employee medical pharmacy claims data from five large corporations including health risk appraisal (HPA) |
| Nutrition program           | Katcher et al 48       | 2010           | USA              | BMI ≥ 25 and/or Type 2 diabetes | Recruited from 2 large corporate sites of an insurance company |
| Self-management program     | Adepoju et al 49       | 2014           | USA              | Type 2                       | Recruited potential subjects selected with electronic medical records from a large university-affiliated healthcare system |
| Employer-supporting program | Bevis et al 50         | 2014           | USA              | Type 2 (Type 1 diabetes was excluded) | Recruited by multimedia publicity on the employer campus and home mailings. Simultaneously sequestered review by the single payer on the basis of previously diagnosed and/or treated diabetes |
| Needed work accommodation   | Gifford et al 51       | 2017           | USA              | Not specific                 | RANS’s Corporation’s American Life Panel with several existing surveys and a representative sample of US consumers. The panel includes about 6000 respondents from over 5000 US households |

Quality of evidence was evaluated with the Newcastle Ottawa Scale and is expressed as number of stars gained/maximum number of stars for each study type.

Quality of evidence was evaluated with the Cochrane Handbook for Systematic Reviews, Version 5.1.0, and is expressed as risk of bias.
| Sample size                                                                                                                                                                                                 | Measure of presenteeism                            | Key conclusions on work productivity including presenteeism                                                                                                                                                                                                 | Research design                   | Quality of evidencea |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|---------------------|
| A total of 115 991 HPA surveys were completed and 64 422 unique employees were included in the survey. A total of 1312 employees had Type 2 diabetes and required insulin, oral hypoglycemic agent, or metformin | Work Performance Questionnaire (HPQ)             | Medication adherence (categorical MPR) is a significant predictor of job performance (absenteeism, presenteeism) for type 2 diabetes with insulin or oral hypoglycemic agent or metformin group. Those with an MPR ≥80% have 2.34 h more work performance over a 28-d period than those with an MPR <80%. However, no significant relationship with absenteeism was observed | Cohort study (retrospective)     | 6/9a                |
| Of 170 who met criteria, 68 participated in the intervention group and 45 participated in the control group                                                                                                   | Work Productivity and Activity Impairment questionnaire, general heath version (WPAL-GH) | Participants in the vegan diet group reported a 40% decrease in the amount that health problems affected their work productivity (absenteeism + presenteeism)                                                                                     | Non-randomized control trial     | Highb               |
| A total of 1897 potential subjects were contacted, 922 of whom voiced their interest in the study. Of these, 376 individuals met the study criteria and agreed to participate in the study                                                                                   | Any impairments or health problems that limited the kind or amount of paid work subjects could perform and multiplied the factors obtained from prior literature | Interventions were personal digital assistant (PDA), chronic disease self-management program (CDSMP), and PDA and CDSMP combined. Presenteeism comprised 44% of total productivity loss, but there were no statistically significant differences among persons undergoing any of the 3 diabetes management interventions compared with subjects in the usual care group | Randomized control trial         | Highb               |
| Of the employees with diabetes, 175 participants in the full 12 mo of the program. Of these, 151 of the 175 employees attended at least 2 educational session and met all inclusion criteria                                                                                     | Total 6-item Stanford Presenteeism Scale (SPS-6) | SPS-6 scores for employees with diabetes were compared at the beginning and the end of the program. There was a highly significant increase in SPS-6 scoring (improvement). Improved stress management and perceived improvement in health were the major contributors to improved scoring. From HbA1c values of 8.02% ± 1.90% at 0 mo, there was significant improvement in HbA1c levels at 6 mo (7.13% ± 1.43%), but the HbA1c improvement slipped to a more modest outcome by 12 mo (7.48% ± 1.52%) | Pre-post intervention comparison | Highb               |
| Of 1396 invited participants, 1174 respondents were followed up. Of these respondents, 7.7% of them had diabetes                                                                                                                                                     | Measured the extent by which health problems affect participants’ work productivity | The odds that an employee who did not receive a needed accommodation reported a higher level of lost productivity are 5.1 times the odds for an employee who received a needed accommodation. However, there were no interactions between chronic health problems, including metabolic problems and accommodations. This suggests that the association between accommodations and productivity loss are similar on average for employees with and without any of the reported problems | Cross-sectional study            | 4/6a                |
4 | DISCUSSION

Diabetes has steadily increased globally, and it is expected that not only direct costs but also indirect costs will also continue to increase. Among them, losses of presenteeism occupy a substantial part of indirect costs of workers; thus, it is considered that countermeasures against presenteeism are more important than the burden of medical expenses from the standpoint of the employer. Also, in supporting workers trying to continue their work while receiving treatment for diabetes, presenteeism, defined as the health-related productivity loss while paid work, is the difficulty of work itself that needs the support. To develop and implement effective measures against presenteeism, it is necessary to clarify the mechanism of its occurrence and consider improvement measures. Therefore, we conducted a systematic review to identify factors that induce presenteeism and methods to improve presenteeism attributed to diabetes.

4.1 | Comorbidities and complications of diabetes which induce presenteeism

Papers on occurrence factors of presenteeism attributed to diabetes were limited and most of them were published after 2011. We adopted NOS to evaluate the quality of evidences for cohort studies and the modified NOS by Breton et al for cross-sectional studies. As a result of the evaluation, they had a low quality of evidence. However, it was found that the associations of hypoglycemia, diabetic neuropathy, and mood disorders with presenteeism had been relatively well studied in this review. This is probably because these comorbidities and complications occur relatively frequently, and reasonably high presenteeism may occur due to accompanying symptoms. However, these comorbidities and complications result from different causes. That is, hypoglycemia is associated with inappropriate treatment and poor adherence. A few papers reported that it caused productivity loss even when the symptoms were not severe or occurred at night, although there are conflicting reports that there was no significant difference in presenteeism between non-severe and no hypoglycemia. Diabetic neuropathy is one of the 3 major complications arising from long-term poor glycemic control, and it is observed that when the pain becomes stronger, larger productivity loss occurs. Although the exact cause remains unclear, diabetes has a high incidence of mood disorders as with other chronic diseases. Presenteeism increases with both diabetes and mood disorders, although the interaction is not recognized. It is also thought that mood disorders affect diabetes control. In addition, presenteeism worsens with worsening of diabetes complications.

4.2 | Possible interventions or conditions which improve presenteeism effectively

Although there is limited information on causes of presenteeism attributed to diabetes, based on the findings obtained in this systematic review, improving diabetes control, evaluating the effect of treatment on work productivity and adjusting treatment, and providing psychological support are expected to be important methods to improve presenteeism. However, intervention studies based on these possibilities have been hardly investigated, as we found out only 4 related studies including randomized control trials (RCTs) with the negative result. As for reduction in presenteeism by glycemic control, Loepke et al observed medication adherence was a significant predictor of job performance, and the results indirectly suggested the effectiveness of improving glycemic control on presenteeism. Although presenteeism was not evaluated, Testa et al compared changes in glycemic control and absenteeism between an active therapy group and a placebo group in a double-blinded RCT and observed that good glycemic control for patients in the active therapy group was associated with greater improvement in absenteeism. They also observed that symptoms of distress and cognitive function improved in the active therapy group. The result suggests the possible reduction in presenteeism by glycemic control. To our knowledge, however, only 2 intervention studies with presenteeism as an outcome have been published: a retrospective observational study that examined the effect of a nutrition program and an RCT of a self-management program.

As for presenteeism due to treatment, inappropriate treatment content and poor adherence increase the likelihood of the occurrence of hypoglycemia. Although we could not find evidence in the relevant literature, it is considered that an increase in urine volume by sodium glucose co-transporter 2 inhibitor may affect job performance. Nakajima et al asked 1300 Japanese patients with diabetes, what diabetes-related issues affected their work and reported 10.5% of respondents answered that they had to frequently use the restroom. The increase in urine volume is considered to have a substantial impact on work productivity for workers who operate in an environment where they cannot freely go to the restroom. Therefore, it is necessary to select treatment regimens according to symptoms and work conditions. Collaboration between diabetes physicians and occupational physicians would be effective.

As diabetes frequently accompanies mood disorders, especially depression, diagnosis and treatment of mood disorders should be considered in the treatment of diabetes. Bogner et al reported the results of an RCT that integrated diabetes management and depression treatment to improve medication adherence and conditions of both diseases. It was also reported that psychological support improves self-efficacy, resulting in improved medication adherence and health behavior, which might lead to improved glycemic control.
control. Bevis et al reported that improved stress management and perceived improvement in health were the major contributors to improved presenteeism scoring by diabetes wellness care at the workplace. Safren et al reported that cognitive behavioral therapy was an effective intervention for adherence, depression, and glycemic control in patients with uncontrolled type 2 diabetes and depression. Therefore, psychological support is also considered to be important for patients without mood disorders. In addition, as it was suggested that presenteeism was alleviated by work accommodations required by workers with diabetes, approaches to improve the work environment and work are also important, as well as those to individuals. Work accommodations should be considered with the understanding of specific issues of individual workers.

4.3 | Limitations

The main limitation is the quantity and quality of papers identified. Most studies were cross-sectional studies and control setting was sometimes insufficient. In addition, in spite that factors associated with each type of diabetes, such as age, duration, and insulin dependency, are different, we analyzed type 1 and type 2 together as they were combined or type was not specified in about half of papers.

Because presenteeism occupies a substantial part of diabetes-associated costs, especially for persons of working age, active investigation is needed.

5 | CONCLUSIONS

Presenteeism attributed to diabetes is caused by hypoglycemia, diabetic neuropathy, and mood disorders. Our systematic review suggested that improving glycemic control, adjusting treatment regimen by evaluating the impact on work productivity, providing psychological support, and developing suitable work accommodations for individual issues can effectively reduce presenteeism. However, further study is necessary considering the significant costs associated with presenteeism attributed to diabetes.

ACKNOWLEDGMENT

We thank Christina Croney, PhD, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.

DISCLOSURE

Approval of the research protocol: N/A. Informed consent: N/A. Registry and the registration no. of the study/trial: N/A. Animal studies: N/A.

CONFLICTS OF INTEREST

None declared.

ORCID

Koji Mori https://orcid.org/0000-0002-8821-4438

REFERENCES

1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50.
2. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137-149.
3. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care. 1998;21(2):296-309.
4. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26(3):917-932.
5. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31(3):596-615.
6. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-1046.
7. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917-928.
8. Sørensen M, Arneberg F, Line TM, et al. Cost of diabetes in Norway 2011. Diabetes Res Clin Pract. 2016;122:124-132.
9. Bolin K, Gip C, Mörk AC, et al. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005—a register-based approach. Diabet Med. 2009;26(9):928-934.
10. Peters ML, Huisman EL, Schoonen M, et al. The current total economic burden of diabetes mellitus in the Netherlands. Neth J Med. 2017;75(7):281-297.
11. Lopez-Bastida J, Boronat M, Moreno JO, et al. Costs, outcomes and challenges for diabetes care in Spain. Global Health. 2013;9:17. https://doi.org/10.1186/1744-8603-9-17.
12. Leśniowska J, Schubert A, Wojna M, et al. Costs of diabetes and its complications in Poland. Eur J Health Econ. 2014;15(6):653-660.
13. Elgart JF, Asteazarán S, De La Fuente JL, et al. Direct and indirect costs associated to type 2 diabetes and its complications measured in a social security institution of Argentina. Int J Public Health. 2014;59(5):851-857.
14. Bermudez-Tamayo C, Besançon S, Johri M, et al. Direct and indirect costs of diabetes mellitus in Mali: a case-control study. PLoS ONE. 2017;12(5):e0176128. https://doi.org/10.1371/journal.pone.0176128.
15. Goetzl RZ, Ozminkowski RJ, Meneades L, et al. Pharmaceuticals—cost or investment? An employer’s perspective. J Occup Environ Med. 2000;42(4):338-351.
16. Goetzl RZ, Guindon AM, Turshen IJ, et al. Health and productivity management: establishing key performance measures, benchmarks, and best practices. J Occup Environ Med. 2001;43(1):10-17.
17. Goetzl RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the “top 10” physical and mental
health conditions affecting six large U.S. employers in 1999. *J Occup Environ Med.* 2003;45(1):5-14.

18. Goetzl RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. *J Occup Environ Med.* 2004;46(4):398-412.

19. Loepke R, Hymel PA, Lofland JH, et al. Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM Expert Panel. *J Occup Environ Med.* 2003;45(4):349-359.

20. Ospina MB, Denny L, Waye A, et al. A systematic review of measurement properties of instruments assessing presenteeism. *Am J Manag Care.* 2015;21(2):e171-185.

21. Breton MC, Guénette L, Amiche MA, et al. Burden of diabetes on the ability to work: a systematic review. *Diabetes Care.* 2013;36(3):740-749.

22. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. *J Occup Environ Med.* 2007;49(6):672-679.

23. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ.* 2015;349:g7647. https://doi.org/10.1136/bmj.g7647.

24. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4(1):1. https://doi.org/10.1186/s40647-015-0037-8.

25. Tang K. Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence. *PharmacoEconomics.* 2015;33(1):31-48.

26. Gisbert JP, Cooper A, Karagiannis D, et al. Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. *Health Qual Life Outcomes.* 2009;7:90. https://doi.org/10.1186/1477-7525-7-90.

27. Michishita R, Jiang Y, Ariyoshi D, et al. Active rest program by workplace units improved the workplace vigor and presenteeism in painful diabetic peripheral neuropathy: the patients’ perspectives. *J Pain.* 2011;12(1):118-126.

28. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: results from the Motivaction Study. *Diabetes Metab Syndr Obes.* 2011;4:401-408.

29. DiBonaventura MD, Link C, Pollack MF, et al. The relationship between patient-reported tolerability issues with oral antidiabetic agents and work productivity among patients having type 2 diabetes. *J Occup Environ Med.* 2011;53(2):204-210.

30. Wells GS, Oconnell B, Peterson D, et al. The Newcastle-Ottawa score for non-randomized studies; 2010 [Online] [cited 2018 September 1]. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

31. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions; 2011 [Online] [cited 2018 September 1]; Available from: URL: http://handbook-5-1.cochrane.org/.

32. Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. *Value Health.* 2011;14(5):665-671.

33. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. *J Med Econ.* 2012;15(1):77-86.

34. Brod M, Wolder M, Christensen T, et al. Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. *Value Health.* 2013;16(8):1140-1149.

35. Brod M, Wolden M, Groeleau D, et al. Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2. *J Med Econ.* 2014;17(1):11-20.

36. Ohashi Y, Wolden M, Hyllested-Winge J, et al. Diabetes management and daily functioning burden of non-severe hypoglycemia in Japanese people treated with insulin. *J Diabetes Investig.* 2017;8(6):776-782.

37. Meneghini LF, Lee JK, Gupta S, et al. Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin. *Diabetes Obes Metab.* 2018;20(5):1156-1165.

38. Awasthi S, Jigal K, Witt EA, et al. Impact of the severity of hypoglycemia on health – related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes. *J Diabetes Complications.* 2018;32(5):451-457.

39. Mitchell BD, Vietri J, Zagar A, et al. Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c. *BMC Endocr Disord.* 2013;13:59. https://doi.org/10.1186/1472-6823-13-59.

40. Lopez JM, Annunziata K, Bailey RA, et al. Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence. *Patient Prefer Adherence.* 2014:8:683-692.

41. DiBonaventura MD, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. *Pain Med.* 2011;12(1):118-126.

42. Taylor-Stokes G, Pike J, Sadosky A, et al. Association of patient-rated severity with other outcomes in patients with painful diabetic peripheral neuropathy. *Diabetes Metab Syndr Obes.* 2011;4:401-408.

43. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. *Diabetes Metab Syndr Obes.* 2013;6:79-92.

44. Bielecky A, Chen C, Ibrahim S, et al. The impact of co-morbid mental and physical disorders on presenteeism. *Scand J Work Environ Health.* 2015;41(6):554-564.

45. Bolge SC, Flores NM, Phan JH. The burden of poor mental well-being among patients with type 2 diabetes mellitus: examining health care resource use and work productivity loss. *Diabetes Metab Syndr Obes.* 2016;58(11):1121-1126.

46. Lee Y, Smofsky A, Nykoliation P, et al. Cognitive impairment mediates workplace impairment in persons with type 2 diabetes mellitus: results from the Motivation Study. *Can J Diabetes.* 2018;42(3):289-295.

47. Loeppke R, Haufle V, Jinnett K, et al. Medication adherence, co-morbidities, and health risk impacts on workforce absence and job performance. *J Occup Environ Med.* 2011;53(6):595-604.

48. Katcher HI, Ferdowsian HR, Hoover VJ, et al. A worksite vegan nutrition program is well-accepted and improves health-related quality of life and work productivity. *Ann Nutr Metab.* 2010;56(4):245-252.
49. Adepoju OE, Bolin JN, Ohsfeldt RL, et al. Can chronic disease management programs for patients with type 2 diabetes reduce productivity-related indirect costs of the disease? Evidence from a randomized controlled trial. Popul Health Manag. 2014;17(2):112-120.

50. Bevis CC, Nogle JM, Forges B, et al. Diabetes wellness care: a successful employer-endorsed program for employees. J Occup Environ Med. 2014;56(10):1052-1061.

51. Gifford B, Zong Y. On-the-job productivity losses among employees with health problems: the role of work accommodations. J Occup Environ Med. 2017;59(9):885-893.

52. Holt RI, de Groot M, Golden SH. Diabetes and depression. Curr Diab Rep. 2014;14(6):491. https://doi.org/10.1007/s11892-014-0491-3.

53. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280(17):1490-1496.

54. Nakajima E; Japan Organization of Occupational Health and Safety. Research reports on development and dissemination of support strategy for balancing work with treatment and for returning to work of workers with diabetes. [Online] [cited 2018 September 1]; Available from: URL: http://www.research.johas.go.jp/booklet/pdf/2nd/12-2.pdf; 2017. (in Japanese)

55. Bogner HR, Morales KH, de Vries HF, et al. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10(1):15-22.

56. Shao Y, Liang L, Shi L, et al. The effect of social support on glycemic control in patients with type 2 diabetes mellitus: the mediating roles of self-efficacy and adherence. J Diabetes Res. 2017;2017:2804178. https://doi.org/10.1155/2017/2804178.

57. Nelson KM, McFarland L, Reiber G. Factors influencing disease self-management among veterans with diabetes and poor glycemic control. J Gen Intern Med. 2007;22(4):442-447.

58. Safren SA, Gonzalez JS, Wexler DJ, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes. Diabetes Care. 2014;37(3):625-633.

How to cite this article: Mori K, Mori T, Nagata T, et al. Factors of occurrence and improvement methods of presenteeism attributed to diabetes: A systematic review. J Occup Health. 2019;61:36-53. https://doi.org/10.1002/1348-9585.12034